"Clozapine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.
| Descriptor ID |
D003024
|
| MeSH Number(s) |
D03.633.300.240.220
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clozapine".
Below are MeSH descriptors whose meaning is more specific than "Clozapine".
This graph shows the total number of publications written about "Clozapine" by people in this website by year, and whether "Clozapine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 4 | 1 | 5 |
| 1999 | 2 | 0 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2008 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clozapine" by people in Profiles.
-
Rahman T, Ash DM, Lauriello J, Rawlani R. Misleading Guidance From Pharmacogenomic Testing. Am J Psychiatry. 2017 Oct 01; 174(10):922-924.
-
Gerken AT, McGahee S, Keuroghlian AS, Freudenreich O. Consideration of Clozapine and Gender-Affirming Medical Care for an HIV-Positive Person with Schizophrenia and Fluctuating Gender Identity. Harv Rev Psychiatry. 2016 Nov/Dec; 24(6):406-415.
-
Anbalagan E, Ithman M, Lauriello J. Rechallenging clozapine after neuroleptic malignant syndrome. Psychiatr Q. 2014 Sep; 85(3):345-8.
-
Weaver LA, De León DD, Borgmann-Winter K, Coffey BJ. Use of metformin to control clozapine-associated weight gain in an adolescent with schizoaffective disorder. J Child Adolesc Psychopharmacol. 2010 Apr; 20(2):153-7.
-
Le Hellard S, Theisen FM, Haberhausen M, Raeder MB, Fern? J, Gebhardt S, Hinney A, Remschmidt H, Krieg JC, Mehler-Wex C, N?then MM, Hebebrand J, Steen VM. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry. 2009 Mar; 14(3):308-17.
-
Ahmed MR, Gurevich VV, Dalby KN, Benovic JL, Gurevich EV. Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation. J Pharmacol Exp Ther. 2008 Apr; 325(1):276-83.
-
Yablonsky-Alter E, Gashi E, Lidsky TI, Wang HY, Banerjee SP. Clozapine protection against gestational cocaine-induced neurochemical abnormalities. J Pharmacol Exp Ther. 2005 Jan; 312(1):297-302.
-
Bustillo J, Wolff C, Myers-y-Gutierrez A, Dettmer TS, Cooper TB, Allan A, Lauriello J, Valenzuela CF. Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels. Schizophr Res. 2004 Jan 01; 66(1):31-9.
-
Sporn A, Gogtay N, Ortiz-Aguayo R, Alfaro C, Tossell J, Lenane M, Gochman P, Rapoport JL. Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol. 2003; 13(3):401-4.
-
Bustillo JR, Lauriello J, Rowland LM, Jung RE, Petropoulos H, Hart BL, Blanchard J, Keith SJ, Brooks WM. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Res. 2001 Oct 01; 107(3):135-49.